227 related articles for article (PubMed ID: 33854039)
1. Metformin for early comorbid glucose dysregulation and schizophrenia spectrum disorders: a pilot double-blind randomized clinical trial.
Agarwal SM; Panda R; Costa-Dookhan KA; MacKenzie NE; Treen QC; Caravaggio F; Hashim E; Leung G; Kirpalani A; Matheson K; Chintoh AF; Kramer CK; Voineskos AN; Graff-Guerrero A; Remington GJ; Hahn MK
Transl Psychiatry; 2021 Apr; 11(1):219. PubMed ID: 33854039
[TBL] [Abstract][Full Text] [Related]
2. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
Freemark M; Bursey D
Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
[TBL] [Abstract][Full Text] [Related]
3. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study.
Wu RR; Jin H; Gao K; Twamley EW; Ou JJ; Shao P; Wang J; Guo XF; Davis JM; Chan PK; Zhao JP
Am J Psychiatry; 2012 Aug; 169(8):813-21. PubMed ID: 22711171
[TBL] [Abstract][Full Text] [Related]
4. Metformin for overweight women at midlife: a double-blind, randomized, controlled trial.
Worsley R; Jane F; Robinson PJ; Bell RJ; Davis SR
Climacteric; 2015 Apr; 18(2):270-7. PubMed ID: 25333776
[TBL] [Abstract][Full Text] [Related]
5. Metformin Improves Peripheral Insulin Sensitivity in Youth With Type 1 Diabetes.
Cree-Green M; Bergman BC; Cengiz E; Fox LA; Hannon TS; Miller K; Nathan B; Pyle L; Kahn D; Tansey M; Tichy E; Tsalikian E; Libman I; Nadeau KJ
J Clin Endocrinol Metab; 2019 Aug; 104(8):3265-3278. PubMed ID: 30938764
[TBL] [Abstract][Full Text] [Related]
6. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial.
Wu RR; Zhao JP; Jin H; Shao P; Fang MS; Guo XF; He YQ; Liu YJ; Chen JD; Li LH
JAMA; 2008 Jan; 299(2):185-93. PubMed ID: 18182600
[TBL] [Abstract][Full Text] [Related]
7. Metformin for prevention of weight gain and insulin resistance with olanzapine: a double-blind placebo-controlled trial.
Baptista T; Martínez J; Lacruz A; Rangel N; Beaulieu S; Serrano A; Arapé Y; Martinez M; de Mendoza S; Teneud L; Hernández L
Can J Psychiatry; 2006 Mar; 51(3):192-6. PubMed ID: 16618011
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.
Klein DJ; Cottingham EM; Sorter M; Barton BA; Morrison JA
Am J Psychiatry; 2006 Dec; 163(12):2072-9. PubMed ID: 17151157
[TBL] [Abstract][Full Text] [Related]
9. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
[TBL] [Abstract][Full Text] [Related]
10. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
11. A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus.
Elkind-Hirsch KE; Seidemann E; Harris R
Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100139. PubMed ID: 33345876
[TBL] [Abstract][Full Text] [Related]
12. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial.
Preiss D; Lloyd SM; Ford I; McMurray JJ; Holman RR; Welsh P; Fisher M; Packard CJ; Sattar N
Lancet Diabetes Endocrinol; 2014 Feb; 2(2):116-24. PubMed ID: 24622715
[TBL] [Abstract][Full Text] [Related]
13. Insulin resistance in type 1 diabetes managed with metformin (INTIMET): Study protocol of a double-blind placebo-controlled, randomised trial.
Snaith JR; Samocha-Bonet D; Evans J; Liu Z; Kowalski G; Bruce C; Holmes-Walker DJ; Greenfield JR
Diabet Med; 2021 Sep; 38(9):e14564. PubMed ID: 33774848
[TBL] [Abstract][Full Text] [Related]
14. Effect of lifestyle interventions with or without metformin therapy on serum levels of osteoprotegerin and receptor activator of nuclear factor kappa B ligand in patients with prediabetes.
Arslan MS; Tutal E; Sahin M; Karakose M; Ucan B; Ozturk G; Cakal E; Biyikli Gencturk Z; Ozbek M; Delibasi T
Endocrine; 2017 Feb; 55(2):410-415. PubMed ID: 27743302
[TBL] [Abstract][Full Text] [Related]
15. Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus.
Bjornstad P; Schäfer M; Truong U; Cree-Green M; Pyle L; Baumgartner A; Garcia Reyes Y; Maniatis A; Nayak S; Wadwa RP; Browne LP; Reusch JEB; Nadeau KJ
Circulation; 2018 Dec; 138(25):2895-2907. PubMed ID: 30566007
[TBL] [Abstract][Full Text] [Related]
16. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study.
Carrizo E; Fernández V; Connell L; Sandia I; Prieto D; Mogollón J; Valbuena D; Fernández I; de Baptista EA; Baptista T
Schizophr Res; 2009 Aug; 113(1):19-26. PubMed ID: 19515536
[TBL] [Abstract][Full Text] [Related]
17. Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin.
Chamarthi B; Cincotta AH
Postgrad Med; 2017 May; 129(4):446-455. PubMed ID: 28374645
[TBL] [Abstract][Full Text] [Related]
18. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
[TBL] [Abstract][Full Text] [Related]
19. Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.
Fontbonne A; Diouf I; Baccara-Dinet M; Eschwege E; Charles MA
Diabetes Metab; 2009 Nov; 35(5):385-91. PubMed ID: 19665415
[TBL] [Abstract][Full Text] [Related]
20. Metformin for treatment of antipsychotic-induced weight gain: a randomized, placebo-controlled study.
Wang M; Tong JH; Zhu G; Liang GM; Yan HF; Wang XZ
Schizophr Res; 2012 Jun; 138(1):54-7. PubMed ID: 22398127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
